Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CGON logo CGON
Upturn stock ratingUpturn stock rating
CGON logo

CG Oncology, Inc. Common stock (CGON)

Upturn stock ratingUpturn stock rating
$34.6
Last Close (24-hour delay)
Profit since last BUY20.68%
upturn advisory
Consider higher Upturn Star rating
BUY since 9 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

09/15/2025: CGON (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

10 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $59

1 Year Target Price $59

Analysts Price Target For last 52 week
$59 Target price
52w Low $14.8
Current$34.6
52w High $40.47

Analysis of Past Performance

Type Stock
Historic Profit -26.13%
Avg. Invested days 23
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 09/15/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 2.54B USD
Price to earnings Ratio -
1Y Target Price 59
Price to earnings Ratio -
1Y Target Price 59
Volume (30-day avg) 10
Beta -
52 Weeks Range 14.80 - 40.47
Updated Date 09/15/2025
52 Weeks Range 14.80 - 40.47
Updated Date 09/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.78

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -28546.1%

Management Effectiveness

Return on Assets (TTM) -12.85%
Return on Equity (TTM) -16.58%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 1882036350
Price to Sales(TTM) 4613.6
Enterprise Value 1882036350
Price to Sales(TTM) 4613.6
Enterprise Value to Revenue 3415.67
Enterprise Value to EBITDA -
Shares Outstanding 76247600
Shares Floating 61016364
Shares Outstanding 76247600
Shares Floating 61016364
Percent Insiders 1.17
Percent Institutions 112.6

ai summary icon Upturn AI SWOT

CG Oncology, Inc. Common stock

stock logo

Company Overview

overview logo History and Background

CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing oncolytic immunotherapies for patients with bladder cancer. Founded in 2010, it has focused on advancing its lead candidate, cretostimogene grenadenorepvec (CG0070), through clinical trials.

business area logo Core Business Areas

  • Oncolytic Immunotherapy Development: Focuses on the research, development, and clinical testing of cretostimogene grenadenorepvec (CG0070) and other oncolytic immunotherapies targeting bladder cancer and other cancers.

leadership logo Leadership and Structure

Arthur Kuan serves as the CEO. The company has a typical structure with departments focused on research, clinical development, regulatory affairs, and commercialization.

Top Products and Market Share

overview logo Key Offerings

  • Cretostimogene Grenadenorepvec (CG0070): CG0070 is an oncolytic immunotherapy designed to selectively replicate in cancer cells, leading to cell lysis and the release of tumor-associated antigens, which stimulate an immune response. It's being investigated for non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guu00e9rin (BCG) therapy. Market share is currently 0%, as the product is not yet approved for commercial sale. Key competitors in the BCG-unresponsive NMIBC space include Merck's Keytruda (approved) and other investigational therapies.

Market Dynamics

industry overview logo Industry Overview

The oncology market, particularly in bladder cancer, is large and growing. There is a significant unmet need for effective therapies for BCG-unresponsive NMIBC, leading to high demand for novel treatments.

Positioning

CG Oncology is positioning itself as a leader in the oncolytic immunotherapy space for bladder cancer, specifically targeting the BCG-unresponsive NMIBC segment. Its competitive advantage lies in the potential efficacy and safety profile of CG0070.

Total Addressable Market (TAM)

The TAM for BCG-unresponsive NMIBC therapies is estimated to be in the billions of dollars annually. CG Oncology is positioned to capture a significant portion of this market if CG0070 is approved. The market continues to grow with the increasing prevalence of bladder cancer and limitations of existing treatments.

Upturn SWOT Analysis

Strengths

  • Promising clinical trial data for CG0070
  • Experienced management team
  • Focus on a specific unmet medical need
  • Proprietary technology platform

Weaknesses

  • Reliance on a single lead candidate
  • Limited commercial infrastructure
  • High cash burn rate typical of development-stage biopharma
  • Dependence on successful completion of clinical trials and regulatory approval

Opportunities

  • Expansion of CG0070 into other cancer indications
  • Partnerships with larger pharmaceutical companies
  • Potential for accelerated regulatory approval
  • Increasing awareness of oncolytic immunotherapy

Threats

  • Clinical trial failures
  • Regulatory setbacks
  • Competition from other therapies
  • Economic downturn impacting funding for biotech companies

Competitors and Market Share

competitor logo Key Competitors

  • MRK
  • BLFS
  • VYGR

Competitive Landscape

CG Oncology is competing in a landscape dominated by established players like Merck (Keytruda). Success hinges on demonstrating superior efficacy and safety compared to existing therapies and other investigational agents. BLFS and VYGR are earlier stage companies exploring alternative approaches for NMIBC.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is defined by the progression of CG0070 through clinical trials.

Future Projections: Future growth is dependent on successful commercialization of CG0070 and potential expansion into other indications. Analyst estimates are subject to clinical trial outcomes.

Recent Initiatives: Recent initiatives include advancing the BONDER-002 trial and preparing for potential commercial launch.

Summary

CG Oncology is a development-stage company with a promising lead candidate in CG0070. The company's success depends on the results of its clinical trials and subsequent regulatory approval. While the company has a focused approach and a strong management team, it faces risks associated with clinical development, competition, and funding. The large unmet need in BCG-unresponsive NMIBC presents a significant market opportunity.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Analyst Reports
  • ClinicalTrials.gov

Disclaimers:

The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About CG Oncology, Inc. Common stock

Exchange NASDAQ
Headquaters Irvine, CA, United States
IPO Launch date 2024-01-25
Chairman & CEO Mr. Arthur Kuan
Sector Healthcare
Industry Biotechnology
Full time employees 113
Full time employees 113

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003, which is in phase 3 clinical trial for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 that is in phase 2 clinical trial to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy that is in phase 3 clinical trial for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008, which is in phase 2 clinical trial for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.